depression

Australian biotech's cortisol blocker fails to improve attention in phase 2 depression study
Fierce Biotech
Mon, 08/12/24 - 11:31 am
Actinogen
cortisol blockers
depression
Alzheimer's disease
clinical trials
Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors
Pharma Voice
Wed, 08/7/24 - 11:22 am
Autobahn Therapeutics
depression
ABX-002
major depressive disorder
J&J seeks expanded approval for antidepressant Spravato
BioPharma Dive
Mon, 07/22/24 - 06:43 pm
JNJ
depression
Spravato
MindBio’s LSD-based drug reduced depression symptoms in Phase IIa trial
Clinical Trials Arena
Thu, 06/20/24 - 11:32 am
MindBio Therapeutics
clinical trials
LSD
depression
MB22001
Karuna's captains set sail in new neuropsychiatric venture called Seaport Therapeutics
Fierce Biotech
Tue, 04/9/24 - 11:43 am
Karuna Therapeutics
Seaport Therapeutics
PureTech Health
funding
anxiety
depression
Engrail closes $157M series B, fueled by investors' renewed interest in neuropsychiatry
Fierce Biotech
Tue, 03/19/24 - 11:58 am
Engrail Therapeutics
funding
neuropsychiatric
anxiety
depression
New weight-loss drugs linked to lower risk of depression: study
Axios
Fri, 02/9/24 - 11:12 am
depression
weight loss
Novo Nordisk
Eli Lilly
Ozempic
Wegovy
Mounjaro
Alto Neuroscience preps IPO to push precision psychiatry therapies through the clinic
Fierce Biotech
Tue, 01/16/24 - 09:54 am
Alto Neuroscience
machine learning
artificial intelligence
IPOs
depression
J&J’s Spravato Bests Quetiapine in Phase III Head-to-Head Depression Study
BioSpace
Thu, 10/5/23 - 10:14 am
JNJ
clinical trials
Spravato
treatment-resistant depression
depression
Quetiapine
Exxua Charts a New Path in Depression Treatment Following FDA Nod
Xtalks
Thu, 09/28/23 - 11:38 pm
Fabre-Kramer Pharmaceuticals
FDA
Exxua
major depressive disorder
depression
Neumora, a richly funded brain drug developer, readies for an IPO
BioPharma Dive
Sun, 08/27/23 - 04:27 pm
Neumora Therapeutics
IPOs
depression
navacaprant
Brii Biosciences aims to come up big where Sage and Biogen fell short
Pharma Voice
Mon, 08/21/23 - 06:53 pm
Brii Biosciences
depression
SAGE Therapeutics
Biogen
BRII-296
postpartum depression
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Sage Stock Drops Despite Promising Phase III Depression Data
BioSpace
Thu, 07/27/23 - 11:30 am
SAGE Therapeutics
zuranolone
Biogen
depression
Relmada, reeling from 2 late-phase flops, plots comeback for depression drug
Fierce Biotech
Fri, 03/24/23 - 10:02 am
Relmada Therapeutics
clinical trials
depression
REL-1017
Eliem drops depression drug, ending pursuit of Biogen-Sage and laying off 55% of team
Fierce Biotech
Fri, 02/10/23 - 10:25 am
Eliem Therapeutics
depression
layoffs
ETX-155
AbbVie's Vraylar, carrying $4B sales target, wins FDA label expansion in depression
Fierce Pharma
Mon, 12/19/22 - 10:05 pm
AbbVie
Vraylar
depression
FDA
Relmada rails against depression data both 'implausible' and 'unplausible' in latest phase 3 flunk
Fierce Biotech
Thu, 12/8/22 - 10:20 am
Relmada
REL-1017
depression
clinical trials
Lusaris Launches with $60M to Advance Psychedelic-Based Depression Therapeutic
BioSpace
Thu, 11/3/22 - 11:00 am
Lusaris Therapeutics
funding
LSR-1019
depression
treatment-resistant depression
Prescriptions for mental health medications hiked during COVID-19
Beckers Hospital Review
Wed, 07/13/22 - 08:23 pm
antidepressants
depression
mental health
COVID-19
pandemic

Pages